 |
Case Report
Human epidermal growth factor 2 (HER2) non-small cell lung cancer (NSCLC) with YVMA mutation responsive to ado-trastuzumab emtansine
1 Brooke Army Medical Center, San Antonio, Texas, USA
Address correspondence to:
Kristin Stoll
DO, San Antonio Uniformed Health Consortium, San Antonio Military Medical Center, 500 Roger Brooke Drive, San Antonio, Texas 78234,
USA
Message to Corresponding Author
Article ID: 100065Z10KS2020
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Stoll K, Peterson M. Human epidermal growth factor 2 (HER2) non-small cell lung cancer (NSCLC) with YVMA mutation responsive to ado-trastuzumab emtansine. J Case Rep Images Oncology 2020;6:100065Z10KS2020.ABSTRACT
Human epidermal growth factor 2/NEU (HER2) aberrations account for 4.7–10% of all non-small cell lung cancers (NSCLC), making it one of the more prevalent forms of NSCLC. Human epidermal growth factor 2 aberrations also instigate breast cancer and these patients commonly demonstrate a robust response to HER targeted immunotherapies. This optimistically promised that HER2 NSCLC might also respond via the same pathophysiologic mechanisms. To date, this promise has largely failed to deliver, and an early trial ended in cancellation due to lack of efficacy. Contrary to this lack of efficacy, this case presents a patient with HER2 positive NSCLC with a specific gene amplification that demonstrated response to HER2 therapy. This adds to the growing evidence that targeted therapy can be efficacious in some HER2 positive NSCLC. It further reinforces the need for extended mutational testing in lung cancer patients, particularly those with a smoking history.
Keywords: Adenocarcinoma of the lung, HER2, HER2 positive lung cancer, NSCLC, Trastuzumab emtansine
SUPPORTING INFORMATION
Author Contributions
Kristin Stoll - Acquisition of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Matthew Peterson - Substantial contributions to conception and design, Acquisition of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guaranter of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2020 Kristin Stoll et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
